+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of secutrelvir for treating symptomatic nonhospitalized adults and adolescents with COVID-19 who are at high risk of developing severe disease. This phase 3 trial compares secutrelvir to a placebo to better understand its impact on preventing worsening illness and serious outcomes like hospitalization or death. Participants will be randomly assigned to receive either secutrelvir or a placebo. Both treatments are given orally as tablets. The study includes multiple assessments from baseline through 28 days, and safety monitoring continues up to 24 weeks after treatment. The trial is double-blind, so neither participants nor researchers know who receives the active drug or placebo. During the study, participants will be monitored for COVID-19 symptoms, viral levels, and health status through various measures such as symptom resolution times, medically attended visits, hospitalizations, and quality of life questionnaires. Blood samples will be collected on specific days to analyze drug levels and any side effects. The main outcome is to see how many participants experience worsening illness or serious events within 28 days of starting treatment.

Age: 12Years +All GendersPhase 3
51 locations
P

Actively Recruiting

Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.

Age: 18Years +All GendersPhase 3
715 locations
E

Actively Recruiting

This research aims to assess the effectiveness and safety of depemokimab GSK3511294 used alone, without intranasal corticosteroids INCS, in Japanese adults with chronic rhinosinusitis with nasal polyps CRSwNP who have not responded well to standard treatments. The study focuses on participants with significant nasal polyp symptoms and evaluates changes in nasal polyp size and symptom relief over time. Participants will receive 100 mg of depemokimab as a monotherapy along with their existing standard care for CRSwNP excluding intranasal corticosteroids. This is a Phase IV, single-arm, open-label study where all participants receive the same treatment and are monitored throughout the study period of up to 52 weeks. During the study, participants will be regularly assessed for nasal polyp size using endoscopic scoring, symptom severity such as nasal obstruction, runny nose, and loss of smell using verbal response scales, and overall quality of life through the Sino-nasal Outcome Test SNOT-22. Imaging with CT scans will also be performed at the start and end of the study. The main outcome measured is the percentage of participants who achieve a significant reduction in nasal polyp size without needing surgery or other nasal treatments by Week 52.

Age: 18Years +All GendersPhase 4
10 locations
R

Actively Recruiting

Researchers are evaluating the safety and clinical effects of Awiqli in people with diabetes mellitus in Japan during routine medical care. This observational study aims to collect real-world data on the use of Awiqli over a one-year period. The study focuses on participants with any type of diabetes who are prescribed Awiqli independently of the study. Participants will receive commercially available Awiqli as directed by their treating doctors according to standard clinical practice. There is no experimental treatment assignment as this is a non-interventional study. The study observes the use of Awiqli over 52 weeks without altering usual care. During the study, participants will be monitored for adverse reactions and events, serious adverse events, and changes in diabetes-related clinical parameters including HbA1c, fasting plasma glucose, and diabetes therapy-related quality of life. Data will be collected from baseline through week 52. The total participation time lasts about one year.

All AgesAll Genders
116 locations
I

Actively Recruiting

Researchers are conducting a survey to monitor the safety and effectiveness of Ondexxya Intravenous Injection 200 mg in patients who have received this treatment. The focus is on understanding the occurrence of specific safety concerns, including thrombotic events, infusion reactions, and re-bleeding, in patients treated for life-threatening bleeding related to Factor Xa inhibitors. The survey gathers information under real-world use conditions to detect any unknown adverse drug reactions, assess the incidence of known adverse effects, and identify factors that may influence the safety or effectiveness of the drug. There are no assigned intervention groups, as this is an observational study collecting data from patients treated with Ondexxya. Participants are monitored for 30 days to evaluate the incidence of adverse drug reactions and safety events related to their treatment. Safety and effectiveness information is collected through routine clinical care without additional interventions. The study will continue until October 31, 2026, with outcomes focused on adverse reactions and safety specifications during the observation period.

All AgesAll Genders
54 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety and tolerability of cenobamate in Japanese patients with partial onset seizures. This Phase 2, multicenter open-label extension study aims to monitor how well patients tolerate cenobamate over an average period of four years. The study is sponsored by Ono Pharmaceutical Co., Ltd. and focuses on patients who have completed a prior related study. Participants receive cenobamate orally once daily throughout the study. The trial does not include a comparison group or placebo, as all participants receive the investigational drug. This extension study follows patients who completed an earlier core study and continues to assess their response to long-term treatment. During the study, participants will undergo regular assessments including blood and urine tests, liver function and hematology panels, vital signs like heart rate and blood pressure, electrocardiograms, and evaluations for potential suicidal thoughts using the Columbia-Suicide Severity Rating Scale. The study aims to track any adverse events and changes in seizure frequency over the four-year period, ensuring close safety monitoring and thorough data collection.

All AgesAll GendersPhase 2
29 locations
O

Actively Recruiting

Researchers are monitoring adults with severe emphysema who are candidates for bronchoscopic lung volume reduction using the Zephyr Endobronchial Valve. This observational study involves 140 patients across up to 20 centers in Japan and follows them for 12 months to evaluate the safety and effects of this treatment approach. Participants must have little to no collateral ventilation in the target lung lobe, confirmed by a specialized bronchoscopy assessment. Participants undergo a bronchoscopy with the Chartis system to check for collateral ventilation. Those confirmed suitable receive the Zephyr Valve placement in the most affected lung lobe. After the procedure, participants stay hospitalized for at least 3 nights for observation and then continue with follow-up visits for one year. A pulmonary rehabilitation program is also required between 45 days and 3 months after the valve placement. Throughout the study, lung function, exercise capacity, breathlessness, and quality of life are assessed at multiple time points. High-resolution CT scans are done at 45 days and 12 months to measure lung volume changes. Safety is monitored by tracking adverse events and the incidence of pneumothorax within 45 days after the procedure. This comprehensive follow-up helps researchers understand the treatments impact and safety profile over time.

Age: 18Years +All Genders
17 locations